Cargando…
The clinical value of using chloroquine or hydroxychloroquine as autophagy inhibitors in the treatment of cancers: A systematic review and meta-analysis
BACKGROUND: Autophagy is a mechanism which relies on lysosomes for clearance and recycling of abnormal proteins or organelles. Many studies have demonstrated that the deregulation of autophagy is associated with the development of various diseases including cancer. The use of autophagy inhibitors is...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257684/ https://www.ncbi.nlm.nih.gov/pubmed/30431566 http://dx.doi.org/10.1097/MD.0000000000012912 |
_version_ | 1783374370247278592 |
---|---|
author | Xu, Ran Ji, Ziyi Xu, Chen Zhu, Jing |
author_facet | Xu, Ran Ji, Ziyi Xu, Chen Zhu, Jing |
author_sort | Xu, Ran |
collection | PubMed |
description | BACKGROUND: Autophagy is a mechanism which relies on lysosomes for clearance and recycling of abnormal proteins or organelles. Many studies have demonstrated that the deregulation of autophagy is associated with the development of various diseases including cancer. The use of autophagy inhibitors is an emerging trend in cancer treatment. However, the value of autophagy inhibitors remains under debate. Thus, a meta-analysis was performed, aiming to evaluate the clinical value of autophagy-inhibitor-based therapy. METHODS: We searched for clinical studies that evaluated autophagy-inhibitor-based therapy in cancer. We extracted data from these studies to evaluate the relative risk (RR) of overall response rate (ORR), 6-month progression-free survival (PFS) rate, and 1-year overall survival (OS) rate. RESULTS: Seven clinical trials were identified (n = 293). Treatments included 2 combinations of hydroxychloroquine and gemcitabine, 1 combination of hydroxychloroquine and doxorubicin, 1 combination of chloroquine and radiation, 2 combinations of chloroquine, temozolomide, and radiation, and 1 hydroxychloroquine monotherapy. Autophagy-inhibitor-based therapy showed higher ORR (RR: 1.33, 95% confidence interval [CI]: 0.95–1.86, P = .009), PFS (RR: 1.72, 95% CI: 1.05–2.82, P = .000), OS (RR: 1.39, 95% CI: 1.11–1.75, P = .000) values than the therapy without inhibiting autophagy. CONCLUSION: This meta-analysis showed that autophagy-inhibitor-based therapy has better treatment response compared to chemotherapy or radiation therapy without inhibiting autophagy, which may provide a new strategy for the treatment of cancers. |
format | Online Article Text |
id | pubmed-6257684 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-62576842018-12-17 The clinical value of using chloroquine or hydroxychloroquine as autophagy inhibitors in the treatment of cancers: A systematic review and meta-analysis Xu, Ran Ji, Ziyi Xu, Chen Zhu, Jing Medicine (Baltimore) Research Article BACKGROUND: Autophagy is a mechanism which relies on lysosomes for clearance and recycling of abnormal proteins or organelles. Many studies have demonstrated that the deregulation of autophagy is associated with the development of various diseases including cancer. The use of autophagy inhibitors is an emerging trend in cancer treatment. However, the value of autophagy inhibitors remains under debate. Thus, a meta-analysis was performed, aiming to evaluate the clinical value of autophagy-inhibitor-based therapy. METHODS: We searched for clinical studies that evaluated autophagy-inhibitor-based therapy in cancer. We extracted data from these studies to evaluate the relative risk (RR) of overall response rate (ORR), 6-month progression-free survival (PFS) rate, and 1-year overall survival (OS) rate. RESULTS: Seven clinical trials were identified (n = 293). Treatments included 2 combinations of hydroxychloroquine and gemcitabine, 1 combination of hydroxychloroquine and doxorubicin, 1 combination of chloroquine and radiation, 2 combinations of chloroquine, temozolomide, and radiation, and 1 hydroxychloroquine monotherapy. Autophagy-inhibitor-based therapy showed higher ORR (RR: 1.33, 95% confidence interval [CI]: 0.95–1.86, P = .009), PFS (RR: 1.72, 95% CI: 1.05–2.82, P = .000), OS (RR: 1.39, 95% CI: 1.11–1.75, P = .000) values than the therapy without inhibiting autophagy. CONCLUSION: This meta-analysis showed that autophagy-inhibitor-based therapy has better treatment response compared to chemotherapy or radiation therapy without inhibiting autophagy, which may provide a new strategy for the treatment of cancers. Wolters Kluwer Health 2018-11-16 /pmc/articles/PMC6257684/ /pubmed/30431566 http://dx.doi.org/10.1097/MD.0000000000012912 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | Research Article Xu, Ran Ji, Ziyi Xu, Chen Zhu, Jing The clinical value of using chloroquine or hydroxychloroquine as autophagy inhibitors in the treatment of cancers: A systematic review and meta-analysis |
title | The clinical value of using chloroquine or hydroxychloroquine as autophagy inhibitors in the treatment of cancers: A systematic review and meta-analysis |
title_full | The clinical value of using chloroquine or hydroxychloroquine as autophagy inhibitors in the treatment of cancers: A systematic review and meta-analysis |
title_fullStr | The clinical value of using chloroquine or hydroxychloroquine as autophagy inhibitors in the treatment of cancers: A systematic review and meta-analysis |
title_full_unstemmed | The clinical value of using chloroquine or hydroxychloroquine as autophagy inhibitors in the treatment of cancers: A systematic review and meta-analysis |
title_short | The clinical value of using chloroquine or hydroxychloroquine as autophagy inhibitors in the treatment of cancers: A systematic review and meta-analysis |
title_sort | clinical value of using chloroquine or hydroxychloroquine as autophagy inhibitors in the treatment of cancers: a systematic review and meta-analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257684/ https://www.ncbi.nlm.nih.gov/pubmed/30431566 http://dx.doi.org/10.1097/MD.0000000000012912 |
work_keys_str_mv | AT xuran theclinicalvalueofusingchloroquineorhydroxychloroquineasautophagyinhibitorsinthetreatmentofcancersasystematicreviewandmetaanalysis AT jiziyi theclinicalvalueofusingchloroquineorhydroxychloroquineasautophagyinhibitorsinthetreatmentofcancersasystematicreviewandmetaanalysis AT xuchen theclinicalvalueofusingchloroquineorhydroxychloroquineasautophagyinhibitorsinthetreatmentofcancersasystematicreviewandmetaanalysis AT zhujing theclinicalvalueofusingchloroquineorhydroxychloroquineasautophagyinhibitorsinthetreatmentofcancersasystematicreviewandmetaanalysis AT xuran clinicalvalueofusingchloroquineorhydroxychloroquineasautophagyinhibitorsinthetreatmentofcancersasystematicreviewandmetaanalysis AT jiziyi clinicalvalueofusingchloroquineorhydroxychloroquineasautophagyinhibitorsinthetreatmentofcancersasystematicreviewandmetaanalysis AT xuchen clinicalvalueofusingchloroquineorhydroxychloroquineasautophagyinhibitorsinthetreatmentofcancersasystematicreviewandmetaanalysis AT zhujing clinicalvalueofusingchloroquineorhydroxychloroquineasautophagyinhibitorsinthetreatmentofcancersasystematicreviewandmetaanalysis |